Vireo Health subsidiary MinnMed has developed a new cannabis product intended to help patients moderate the delivery of THC.  The company’s “MinnMed Silver” product is a prefilled vaporizer cartridge containing a formulation of natural ingredients and a small amount of THC (tetrahydrocannabinol) that has been introduced at the same time as the state has expanded its list of qualifying conditions to include chronic pain. The product, according to the company, is designed for pain patients currently using opioid-based medicine that have no prior experience with cannabis and want to minimize the common side effects associated with this treatment option.  The MinnMed Silver formulation, according to Vireo, can ensure that patients without experience with cannabis don’t get more THC than then they need.

Seniors and other patients are understandably wary of side effects. While the side effects associated with cannabis are much milder than patients have with opioid painkillers, our new MinnMed Silver formulation will help patients go slow and only get as much medicine as they need.

Kyle Kingsley, M.D., Chief Executive Officer of MinnMed
and its parent company Vireo Health

As an emergency medicine physician, I saw that many seniors were opioid victims. With seniors disproportionately suffering from pain and suffering opioid-related tragedies, we need to help them overcome their cannabis-related concerns

Exclusive article by Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email